BACKGROUND

4.1 million cases of CAD (Coronary Artery Diseases including heart attack, unstable angina…) were diagnosed worldwide in 12 million of patients presenting with acute coronary syndromes in 2012.

Atherosclerosis is the leading cause of CAD. Methods of diagnosing atherosclerosis early in the disease process are needed so that affected patients can receive the necessary interventions to prevent further disease progression.

HOW IT WORKS

s-RNY, a subtype of non-coding RNAs, modulate apoptosis and inflammatory response in lipid-laden macrophages within atherosclerotic lesions.

Researchers demonstrated a significant upregulation of s-RNY expression in the serum of patients post-heart attack (308 patients CAD vs. 514 healthy individuals CTL).

KEY BENEFITS vs. STATE OF THE ART

DEVELOPMENT STATUS

We aim at validating on a biobank the s-RNY as predictive biomarkers for:

• A first heart attack
• Subsequent heart attack (20% of the cases)

APPLICATIONS

Prevention/monitoring of patients at risk for heart attacks